Stockscreener 앱 받기
184.79
0.20%
0.395
전일 마감가:
$184.40
열려 있는:
$183.51
하루 거래량:
544.32K
Relative Volume:
0.53
시가총액:
$20.66B
수익:
$9.54B
순이익/손실:
$841.00M
주가수익비율:
24.84
EPS:
7.44
순현금흐름:
$1.02B
1주 성능:
+3.55%
1개월 성능:
+11.01%
6개월 성능:
+7.28%
1년 성능:
+20.79%
1일 변동 폭
$182.84
$185.26
1주일 범위
$177.27
$185.26
52주 변동 폭
$146.17
$185.26
퀘스트 다이아그노스틱스 Stock (DGX) Company Profile
명칭
Quest Diagnostics Inc
전화
(973) 520-2700
주소
500 PLAZA DRIVE, SECAUCUS
DGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
184.80 | 20.01B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
485.23 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.73 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
635.39 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
117.56 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
186.09 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
퀘스트 다이아그노스틱스 Stock (DGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Redburn Atlantic | Buy |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | Jefferies | Buy |
| 2024-10-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | 재개 | Evercore ISI | In-line |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 개시 | Barclays | Equal Weight |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-29 | 개시 | Piper Sandler | Neutral |
| 2023-05-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-23 | 개시 | Evercore ISI | In-line |
| 2022-11-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-04-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-01-28 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-05-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-03-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | 업그레이드 | Argus | Hold → Buy |
| 2020-07-29 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-09 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-04-28 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-04-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-04-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-03-18 | 재개 | Credit Suisse | Neutral |
| 2019-01-31 | 다운그레이드 | Argus | Buy → Hold |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2019-01-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
퀘스트 다이아그노스틱스 주식(DGX)의 최신 뉴스
Decoding Insider Sales at Quest Diagnostics: Is This a Sign of Overvaluation or Prudent Diversification? - AInvest
Plewman, Quest Diagnostics SVP, sells $355k in stock - Investing.com
Quest Diagnostics Introduces Testing for Oropouche Virus - Eastern Progress
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference - Eastern Progress
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare C - GuruFocus
Leading Diagnostics Provider Quest Diagnostics CEO to Share Market Insights at Baird Healthcare Conference - Stock Titan
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - Yahoo Finance
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on October 20, 2025 - MarketScreener
Quest Diagnostics Declares Quarterly Cash Dividend of $0.80 per Share - AInvest
Medical Testing Giant Quest Diagnostics Maintains $0.80 Quarterly Dividend Payout - Stock Titan
Published on: 2025-08-12 17:41:01 - sundaytimes.kr
Quest Diagnostics acquires Fresenius lab assets for dialysis - NJBIZ
Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection - Stock Titan
Quest Diagnostics (DGX) Insider Plans $968k Share Sale – Form 144 | SBS SEC FilingForm 6-K - Stock Titan
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - MSN
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - MarketScreener
Quest Diagnostics Takes Over Fresenius Labs, Set to Serve 200,000 Dialysis Patients Annually - Stock Titan
How many analysts rate Quest Diagnostics Incorporated as a “Buy”Get exclusive market analysis for investors - Jammu Links News
What is Quest Diagnostics Incorporated company’s growth strategyTremendous gains - Jammu Links News
Quest Diagnostics Incorporated Stock Analysis and ForecastFree Predictions - Jammu Links News
What are the technical indicators suggesting about Quest Diagnostics IncorporatedMaximize your returns with expert insights - Jammu Links News
What catalysts could drive Quest Diagnostics Incorporated stock higher in 2025Turbocharged investment results - Jammu Links News
Quest Diagnostics Raises 2025 Guidance - AOL.com
Quest Diagnostics Insider Selling: A Signal of Caution or a Strategic Move Amid Strong Fundamentals? - AInvest
Published on: 2025-08-01 19:05:55 - metal.it
Is Quest Diagnostics Incorporated stock overvalued or undervaluedFinancial News Updates Backed By Experts - Jammu Links News
Earnings visualization tools for Quest Diagnostics IncorporatedVerified Signal From Chart Patterns Detected - metal.it
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
Quest Diagnostics Breakthrough: New Long-Read DNA Test Revolutionizes Ataxia Movement Disorder Detection - Stock Titan
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
What makes Quest Diagnostics Incorporated stock price move sharplyTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
What is the risk reward ratio of investing in Quest Diagnostics Incorporated stockInvest smarter with real-time trading alerts - jammulinksnews.com
Why is Quest Diagnostics Incorporated stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Published on: 2025-07-28 06:28:08 - jammulinksnews.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest and CVS test co-location strategy in Rhode Island - The Business Journals
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon - 富途牛牛
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
퀘스트 다이아그노스틱스 (DGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
0.06%
자본화:
|
볼륨(24시간):